Business Description
Amylyx Pharmaceuticals Inc
NAICS : 325412
SIC : 2834
ISIN : US03237H1014
Description
Amylyx Pharmaceuticals Inc is a clinical-stage pharmaceutical company working on developing a novel therapeutic for amyotrophic lateral sclerosis and other neurodegenerative diseases. It has one operating segment which is the business of researching and developing therapeutics for neurodegenerative disorder.
Financial Strength
7/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Cash-To-Debt | 101.05 | |||||
Equity-to-Asset | 0.78 | |||||
Debt-to-Equity | 0.01 | |||||
Debt-to-EBITDA | -0.05 | |||||
Interest Coverage | N/A |
N/A
|
N/A
| |||
Piotroski F-Score | 6/9 | |||||
Altman Z-Score | 0.71 | |||||
Beneish M-Score | -1.53 | |||||
WACC vs ROIC |
Growth Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Future 3-5Y EPS without NRI Growth Rate | -230.2 |
Momentum Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
5-Day RSI | 63.56 | |||||
9-Day RSI | 47.62 | |||||
14-Day RSI | 35.76 | |||||
6-1 Month Momentum % | -86.15 | |||||
12-1 Month Momentum % | -92.46 |
Liquidity Ratio
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Current Ratio | 4.48 | |||||
Quick Ratio | 4.48 | |||||
Cash Ratio | 4.07 | |||||
Days Inventory | 63.29 | |||||
Days Sales Outstanding | 25.82 | |||||
Days Payable | 45.62 |
Dividend & Buy Back
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -13.8 | |||||
Shareholder Yield % | 1.64 |
Profitability Rank
2/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Gross Margin % | 65.69 | |||||
Operating Margin % | -20.42 | |||||
Net Margin % | -17.86 | |||||
FCF Margin % | 3.88 | |||||
ROE % | -18.56 | |||||
ROA % | -15.71 | |||||
ROIC % | -177.77 | |||||
ROC (Joel Greenblatt) % | -444.86 | |||||
ROCE % | -21.08 | |||||
Years of Profitability over Past 10-Year | 1 |
GF Value Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
PS Ratio | 0.29 | |||||
PB Ratio | 0.37 | |||||
Price-to-Tangible-Book | 0.37 | |||||
Price-to-Free-Cash-Flow | 7.95 | |||||
Price-to-Operating-Cash-Flow | 7.42 | |||||
EV-to-EBIT | 3.04 | |||||
EV-to-EBITDA | 3.09 | |||||
EV-to-Revenue | -0.62 | |||||
EV-to-Forward-Revenue | 1.84 | |||||
EV-to-FCF | -16.14 | |||||
Price-to-Net-Current-Asset-Value | 0.38 | |||||
Price-to-Net-Cash | 0.43 | |||||
Earnings Yield (Greenblatt) % | 32.89 | |||||
FCF Yield % | 12.9 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:AMLX
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Amylyx Pharmaceuticals Inc Executives
DetailsGF Value
Analyst Estimate
Key Statistics
Name | Value | ||
---|---|---|---|
Revenue (TTM) (Mil $) | 398.001 | ||
EPS (TTM) ($) | -1.07 | ||
Beta | 0 | ||
Volatility % | 93.34 | ||
14-Day RSI | 35.76 | ||
14-Day ATR ($) | 0.122949 | ||
20-Day SMA ($) | 1.76925 | ||
12-1 Month Momentum % | -92.46 | ||
52-Week Range ($) | 1.65 - 26.34 | ||
Shares Outstanding (Mil) | 68.01 |
Piotroski F-Score Details
Year:
Component | Result | ||
---|---|---|---|
Piotroski F-Score | 6 | ||
Positive ROA | |||
Positive CFROA | |||
Higher ROA yoy | |||
CFROA > ROA | |||
Lower Leverage yoy | |||
Higher Current Ratio yoy | |||
Less Shares Outstanding yoy | |||
Higher Gross Margin yoy | |||
Higher Asset Turnover yoy |
Amylyx Pharmaceuticals Inc Filings
Filing Date | Document Date | Form | ||
---|---|---|---|---|
No Filing Data |
Amylyx Pharmaceuticals Inc Stock Events
Event | Date | Price($) | ||
---|---|---|---|---|
No Event Data |
Amylyx Pharmaceuticals Inc Frequently Asked Questions
What is Amylyx Pharmaceuticals Inc(AMLX)'s stock price today?
The current price of AMLX is $1.76. The 52 week high of AMLX is $26.34 and 52 week low is $1.65.
When is next earnings date of Amylyx Pharmaceuticals Inc(AMLX)?
The next earnings date of Amylyx Pharmaceuticals Inc(AMLX) is 2024-08-09 Est..
Does Amylyx Pharmaceuticals Inc(AMLX) pay dividends? If so, how much?
Amylyx Pharmaceuticals Inc(AMLX) does not pay dividend.
Press Release
Subject | Date | |||
---|---|---|---|---|
No Press Release |